Cardiff Oncology, Inc.

Cardiff Oncology Inc. is a biotechnology company focused on the development of precision medicine therapies for cancer treatment. The primary purpose of the organization is to create innovative oncological solutions that target specific genetic profiles of tumors, aiming to improve outcomes for cancer patients. Cardiff Oncology's flagship product, Onvansertib, is an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor currently undergoing clinical trials for various malignancies, including colorectal cancer, castration-resistant prostate cancer, and acute myeloid leukemia. By applying a targeted therapeutic approach, the company seeks to address unmet needs in oncology therapies. Cardiff Oncology plays a significant role in the biotechnology sector by contributing to personalized cancer treatment research, which holds the potential to transform standard care practices. Based in San Diego, California, the company is actively involved in collaborations and research initiatives that explore novel treatment options, reinforcing its commitment to advancing medical science and improving patient quality of life.